The immunology and immunotherapy for COVID-19

Expert Rev Mol Med. 2021 Dec 17:23:e24. doi: 10.1017/erm.2021.30.

Abstract

The ongoing global pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and significantly impacts the world economy and daily life. Symptoms of COVID-19 range from asymptomatic to fever, dyspnoea, acute respiratory distress and multiple organ failure. Critical cases often occur in the elderly and patients with pre-existing conditions. By binding to the angiotensin-converting enzyme 2 receptor, SARS-CoV-2 can enter and replicate in the host cell, exerting a cytotoxic effect and causing local and systemic inflammation. Currently, there is no specific treatment for COVID-19, and immunotherapy has consistently attracted attention because of its essential role in boosting host immunity to the virus and reducing overwhelming inflammation. In this review, we summarise the immunopathogenic features of COVID-19 and highlight recent advances in immunotherapy to illuminate ideas for the development of new potential therapies.

Keywords: COVID-19; Cellular exhaustion; SARS-CoV-2; cytokine storm; immunopathology; immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • COVID-19*
  • Humans
  • Immunologic Factors
  • Immunotherapy
  • Pandemics
  • SARS-CoV-2

Substances

  • Immunologic Factors